By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
PR Newswire NORTH CHICAGO, Ill., April 8, 2025 NORTH CHICAGO, Ill., April 8, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ® (upadacitinib; 15 mg, once ...
PR Newswire SEONGNAM, South Korea, April 6, 2025 - ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL Bio's Grabody-B platform technology to ...
PR Newswire PRINCETON, N.J., April 6, 2025 PRINCETON, N.J., April 6, 2025 /PRNewswire/ -- Luye Pharma Group today announced that ERZOFRI® (paliperidone palmitate) extended-release injectable suspension is now available for commercial sale in ...
PR Newswire PARAMUS, N.J., April 4, 2025 PARAMUS, N.J., April 4, 2025 /PRNewswire/ -- SK Life Science, Inc., a global leader in developing treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., ...
PR Newswire SPRING HOUSE, Pa., April 4, 2025 TREMFYA® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...
PR Newswire THOUSAND OAKS, Calif., April 3, 2025 Breakthrough CD19+ B-Cell Targeted Therapy Delivered an 87% Reduction in the Risk of Flares Versus Placebo UPLIZNA Shown to Deliver Corticosteroid-Free, Flare-Free, Complete Remission for ...
Number of patients reached in 2024 jumps 8% to 66 million R&D investments rise to EUR 6.2 billion, 23.2% of group net sales Company prepares new product launches starting in 2025 Boehringer Ingelheim today announced a ...
Canada NewsWire OTTAWA, ON, April 1, 2025 OTTAWA, ON, April 1, 2025 /CNW/ - Summary Affected productsUnauthorized injectable peptide drugs, including: • ARA 16 • ARA 290 • BPC-157 • CJC-1295 • DSIP without ...
More than 92% of schizophrenia patients taking TEV- ' 749 in the SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication 1 New data from UZEDY ® (risperidone) evaluated ...
PR Newswire SAN DIEGO, March 27, 2025 Positive Topline Data from the Fourth Cohort of Patients Consistent demonstration of polycystin (PC) biomarker impact confirming 300 mg fixed dose selection to achieve optimal kidney exposure ...
Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both kidney function and heart health outcomes.
Semaglutide, a diabetes drug, significantly lowers the risk of heart attacks and strokes in people with type 2 diabetes.
Nitisinone shows potential as a new tool for malaria control by making human blood lethal to mosquitoes.
In former and current smokers Statins may reduce chest muscle loss in smokers, while aspirin could increase it.
Vedolizumab outperforms infliximab in ulcerative colitis patients who fail first-line treatment, achieving better steroid-free remission and endoscopic improvements by week 14.
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2025
Careers